Rachel McCoy, NP
Pain Medicine · Greensboro, NCNPI 1477116424
Payments from drug & device makers
Across 141 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$551
- Lilly USA, LLC$337
- Novo Nordisk$328
- Collegium Pharmaceutical, Inc.$234
- Amgen$98
- Pfizer$84
- plus $633 from 23 others
What the payments were for
- Food & beverage$2,265100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $551 |
| Lilly USA, LLC | 21 | $337 |
| Novo Nordisk | 26 | $328 |
| Collegium Pharmaceutical, Inc. | 13 | $234 |
| Amgen | 6 | $98 |
| Pfizer | 6 | $84 |
| Forte Bio-pharma LLC | 3 | $62 |
| Indivior Inc. | 2 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $52 |
| GSK | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $51 |
| Boehringer Ingelheim | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Valinor Pharma, LLC | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Medtronic | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Ardelyx, Inc. | 1 | $16 |
| Shield Therapeutics Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Redhill Biopharma Inc. | 1 | $12 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $12 |
| Genentech USA, Inc. | 1 | $4 |
How this compares
$2,265 in reported general payments places this provider in the 35th percentile of 182 pain medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $120,626 |
| MounjaroTirzepatide | 81 | $115,212 |
| BelbucaBuprenorphine Hcl | 91 | $92,810 |
| Humira(Cf) PenAdalimumab | 13 | $88,194 |
| LinzessLinaclotide | 74 | $62,046 |
| UbrelvyUbrogepant | 20 | $33,914 |
| Xtampza ErOxycodone Myristate | 62 | $33,079 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 666 | $32,185 |
| Oxycodone Hcl | 689 | $18,703 |
| TrulicityDulaglutide | 12 | $17,233 |
| QuliptaAtogepant | 13 | $16,533 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $16,086 |
| Buprenorphine | 84 | $14,647 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 294 | $12,303 |
| EliquisApixaban | 16 | $12,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $337 | $132,44493 claims |
| Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er | $234 | $125,889153 claims |
| Novo NordiskOzempic | $328 | $120,62661 claims |
| AbbVieLinzess, Ubrelvy, Qulipta | $551 | $112,494107 claims |
| PfizerEliquis, Lyrica | $84 | $22,27327 claims |
| Hikma Pharmaceuticals USABuprenorphine, Buprenorphine-Naloxone | $17 | $19,814106 claims |
| GSKBreo Ellipta | $51 | $9,45023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 182 pain medicine providers in North Carolina.
Other pain medicine in Greensboro
- Enrico JonesGreensboro$38K
- Kyle SebastianGreensboro$14K
- Dave EichmanGreensboro$12K
- Yun SunGreensboro$9K
- Leonardo KapuralWinston Salem$4.1M
- James NorthWinston Salem$3.7M
- Richard RauckWinston Salem$1.7M
- Christopher GilmoreWinston Salem$1.3M
- Binit ShahHuntersville$863K
- Jeffrey PeacockWinston Salem$553K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.